ライフサイエンスコーパス: early therapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 infected individuals who were all started on early therapy.

2 han 12 months) may also receive benefit from early therapy.

3 n ganciclovir is given for prophylaxis or as early therapy.

4 ttle is known about the virologic effects of early therapy.

5 With early therapy (4 -9 hours postinfection) lysostaphin ste

6 Early therapy after onset of hyperglycemia and complete

7 e on the basis of recent trials showing that early therapy can be potentially beneficial to patients.

8 day 7 PET follow-up may be exploited toward early therapy change, especially for the 15% of patients

9 ental etiology for AT and could advocate for early therapies for AT patients.

10 nce interval, -1.83 to 4.32; P=0.42) for the early therapy group and 0.55 (95% confidence interval, -

11 d cellular infiltration and bone loss in the early therapy group, and reduced T cell proliferation in

12 single dose after collagen boost on day 21 (early therapy group, or as a single dose upon acquisitio

13 sease severity in the prophylactic group and early therapy group, reduced cellular infiltration and b

14 nts in the delayed-therapy group than in the early-therapy group (30 percent vs. 60 percent) had plas

15 linked transmissions, only 1 occurred in the early-therapy group (hazard ratio, 0.04; 95% CI, 0.01 to

16 f death of 69%, as compared with that in the early-therapy group (relative risk in the deferred-thera

17 bove each of the two thresholds of interest (early-therapy group) with that of patients who deferred

18 Subjects receiving early therapy had fewer treatment end points (hazard rat

19 This may be relevant for the timing of early therapy interventions in infants with pre- and per

20 nt to contain HCV replication, and also that early therapy is effective independent of such responses

21 ute to increased mortality, but nonselective early therapy may result in excess costs and drug resist

22 nd initially elevated AFP, possibly enabling early therapy monitoring independent of morphology.

23 commodate immune escape, we hypothesize that early therapy of primary infection may be beneficial des

24 Early therapy of sepsis involving fluid resuscitation an

25 Additionally, the influence of early therapy on these responses and their relationships

26 e antiretroviral therapy either immediately (early therapy) or after a decline in the CD4 count or th

27 y according to age--three months or younger (early therapy) or older than three months (delayed thera

28 Early therapy response evaluation was assessed by (99m)T

29 Methods: Early therapy response evaluation was assessed by (99m)T

30 ition, sPLA(2) may be useful for instituting early therapies to prevent or reduce the clinical morbid

31 Early therapies treated most patients with asthma simila

32 We tested the hypothesis that early therapy with inhaled glucocorticoids would decreas

33 Early therapy with neuraminidase (NA) inhibitors, either

34 atients who are asymptomatic and instituting early therapy would improve neurologic outcome.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。